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Chronic breathlessness is associated with depression, but its relationship to anxiety is less 
clear. 
Objectives 
This study evaluated associations between chronic breathlessness and: anxiety; depression; 
functional status in the general population. 
Methods 
This cross sectional cohort of consenting adults (≥18 years) used an online survey. Quota 
sampling (n=3,000) was employed reflecting the 2016 national census for sex, age and place 
of residence. Other data included: Patient Health Questionnaire for Depression and Anxiety 
(PHQ-4); the modified Medical Research Council (mMRC) breathlessness scale and the 
Australia-modified Karnofsky Performance Scale (AKPS). Multinomial logistic regression 
assessed predictors.   
Results 
2977 respondents had all relevant scores; female- 51.2%; median age 45.0 (range 18-92). 
Prevalence of breathlessness (mMRC ≥ 2) was 2.4%; anxiety 6.0%; depression 2.7%; co-
existing anxiety/depression 6.1% and poorer functional status (AKPS ≤60) 1.6%. 
Poorest function was in the co-existing anxiety/depression group with 11.6%. The highest 
proportions of people with breathlessness were found in the co-existing anxiety/depression 
group (10.6%) and depression only (8.8%). 
In multinomial regression, depression only and co-existing anxiety/depression were predicted 
by older age, longer duration of breathlessness, and poorer functional status (AKPS ≤60). The 
relationship between poorer functional status and co-existing anxiety/depression was striking 
(OR 16.1; 95% 8.3, 31.4).  
Adjusted odds ratios for breathlessness and: depression only was 5.5 (95% CI 2.3,12.9); and 
5.1 for co-existing anxiety/depression group (95% CI 2.7,9.7). 
Conclusion  
Clinically important breathlessness (mMRC ≥2) was associated with depression only and co-
existing anxiety/depression. Poorer function associated with psychological morbidity in the 
general population requires further research.    
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Chronic breathlessness is a distinct clinical syndrome.[1] It is highly prevalent across high 
income countries, with the likelihood of even higher rates in low and middle income 
countries.[2-4]  Disabling breathlessness in daily life due to chronic breathlessness (measured 
on the modified Medical Research Council breathlessness scale (mMRC)[5]) is experienced 
by 2.6% of the population.[5,6] Chronic breathlessness is clinically under-recognised [7] and, 
even when recognised, under-treated.[8] Chronic breathlessness is associated with poorer 
physical and mental quality of life, [9] increased health service utilisation, [10,11] and is 
strongly correlated with depressive symptoms and poorer survival. [12] The picture for 
anxiety and its impact on chronic breathlessness at the general adult population level is less 
clear although an association has been noted in older adults.[13] It is likely that researchers 
and clinicians may have simply extrapolated the effects of acute breathlessness and anxiety 
into the context of chronic breathlessness. 
 
Anxiety and depression are also highly prevalent across the community; they often coexist, 
[10] are under-recognised and under-treated. [10-14] Lifetime prevalence rates for anxiety are 
16.6% in people aged 18-64 years. [14] Using measurement tools from those on which this 
study relies (Patient Health Questionnaire Depression Scale (PHQ-9) and the Generalized 
Anxiety Disorder Scale (GAD-7)), Swedish population lifetime prevalence estimates for one 
or both conditions demonstrate significant overlap of the two conditions: depression 17.2% 
(95% confidence intervals (CI) 15.1, 19.4); anxiety 14.7% (95% CI 12.7, 16.6); and both 
28.2%. [15]  
 
The relationship between anxiety, depression and chronic breathlessness in the general 
population is poorly delineated. Many chronic conditions are associated with psychological 
comorbidity, limiting care options and self-management, [16] and worsening clinical 
outcomes. [17] However, most of these studies have been done in relation to diagnostic 
groups, such as people with chronic obstructive pulmonary disease (COPD) or heart failure, 
rather than in relation to the symptom itself. In addition, study cohorts are mostly of people 
who have had contact with health services. Given two phase III trials of anxiolytics in chronic 
breathlessness were strongly negative, [18,19] a better understanding of the relationship 
between anxiety and chronic breathlessness at a population level, independent of health 
service utilisation, is timely. The current study specifically targets the general population to 
gain a view about any potential relationship, independently of health service contact. 
The aim of the present study was to evaluate the associations between chronic breathlessness 




Study design and population 
This was a population-based, cross sectional cohort study conducted in November 2018, 
using an online data collection survey of people 18 or older who had provided consent to be 
contacted for such surveys and reconfirmed consent at the time of participation. A quota 
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sampling survey was performed, aligned to industry standards and best practices; up to 
30,000 potential respondents for each sex were invited from a market research data collection 
company’s database of double opt in - registered respondents to ensure 3,000 eligible 
responses. Quotas were created so the final sample frame was representative of the 
characteristics of the Australian population reflecting the 2016 national census by sex, age 
(18-34; 35-44; 45-54; 55-64; ≥65), state or territory of residence, and metropolitan/non-
metropolitan. This was a quota-governed survey where ‘cells’ were created to match the 
national demographic combining each of these four parameters. Working towards the 
nationally representative cell targets where everyone who accepted the invitation to complete 
a survey (topic unspecified) initially qualified, as each demographic ‘cell’ was filled with the 
required number of representative respondents, subsequent respondents who met those 
demographic criteria did not proceed to the full questionnaire.  The study can therefore be 
replicated in a different population by setting these identical parameters. The proportion of 
‘over-subscription’ for each demographic cell is unknown.   
 
Data collection and key measures 
 
Anxiety and depression were assessed using the Patient Health Questionnaire for Depression 
and Anxiety (PHQ-4); a validated ultra-brief screening tool to detect clinically important 
anxiety, depression or both. [20] The two questions on anxiety were derived from the 
Generalized Anxiety Disorder-7 item scale (GAD-7) into the GAD-2, and the two questions 
on depression were derived from the PHQ-9 into the PHQ-2. GAD-2 and PHQ-2 scores can 
be analysed separately or, using the PHQ-4, together. Scores for each question range from 0-
3 giving a potential total of 0-12 for the PHQ-4. Higher scores reflect higher levels of 
depression or anxiety. Clinically important differences were dichotomised according to the 
recommended threshold of  >3 for each subscale creating four mutually exclusive groups: 
‘No Anxiety or Depression’; ‘Anxiety only’; ‘Depression only’; and ‘Co-existing 
Anxiety/Depression’. 
 
Chronic breathlessness was assessed using the five point (0-4) ordinal modified mMRC 
breathlessness scale; a widely used scale designed for large-scale epidemiological studies. 
[5,21] Higher scores reflect worse disability and impact on function related to breathlessness. 
The scale reflects the level of exertion that induces breathlessness sufficient to have an 
impact on the respondent. Higher scores reflect increasing functional impairment by 
breathlessness. A score of ≥2 is likely to represent breathlessness-related disability 
experienced on a daily basis, so the population was dichotomised at that point for all 
analyses. Respondents who reported breathlessness (score >0) were asked about its duration 
in months and years to build on previous estimates. [22] 
 
Functional status was assessed using the AKPS, an 11-point ordinal scale (0-100 in 10 point 
increments). [23] Higher scores indicate better functional status. Scores below 70 indicate an 
increasing need for help from other people in activities of daily living, so data in this study 




See Appendix 1 for the complete survey questions across all four domains (anxiety, 




Respondents’ characteristics were compared between anxiety/depression status using a chi-
square test for categorical variables and analysis of variance (ANOVA) or Kruskal-Wallis for 
continuous variables depending on the nature of the data. Multinomial logistic regression was 
carried out to assess the predictors of group membership for the anxiety/depression status. 
Odds ratios (OR), adjusted odds ratio (AOR) and 95% confidence interval (CI) for the 
likelihood of being breathless were examined using multiple logistic regression. Adjustments 
were made for age, sex and functionality of the respondents.  
 
Analyses were conducted using the Statistical Package for the Social Sciences (SPSS) 
software Version 24.0 (Armonk, NY: IBM Corporation, 2016). A p-value < 0.05 or CI not 
including one was considered statistically significant. 
 
To confirm the representative nature of the sample, the data were weighted by the same key 
characteristics of the 2016 Australian Census [24,25] with no change in weighted data, 
reflecting closely the current national population. As such, no weightings were applied to the 




Given the nature of the survey, no data were imputed.  
 
Ethics approval and consent 
 
This was a community survey governed under the Australian Market and Social Research 
Society code of conduct that aligns with best global practice for social online research survey 
and quantitative data collection. No identifying information was collected for individual 
respondents. Consent was provided at two separate points: at the time of joining the database 




In November 2018, once 3000 eligible adults had responded, the cohort for the study was 
formed. There were missing scores for both anxiety and depression for 24 respondents, 
leaving 2977 people for the final analysis. Demographic characteristics of the study sample 
closely matched those of the Australian population aged 18 and above on sex (female: 51.2% 
and 50.2% respectively), median age (45.0 vs. 45.0 years), the state or territory of residence 




The prevalence of clinically important breathlessness (mMRC ≥ 2) was 2.4% in the 
population (n=72). Anxiety alone was present in 6.0% (n=179) of the population and 
depression in 2.7% (n=80). Coexisting anxiety/depression was present in 6.1% of the cohort 
(n=181). Decreased functional status (AKPS ≤60) was found in 1.6% (n=49) of respondents 
(Table 2). 
 
Characteristics for each of the psychological morbidities are presented in Table 2. Age, 
experiencing breathlessness, duration of breathlessness and functionality were significantly 
associated with psychological morbidity. From an age perspective, the highest median age 
was recorded for those in the group with no anxiety or depression. From a gender perspective 
a higher proportion of females was noted within the anxiety-only group. The highest 
proportion of those with decreased functionality was in the co-existing anxiety/depression 
group with 11.6% (n=21). The highest proportions of people with breathlessness were found 
in the co-existing anxiety/depression group and depression only group with 10.6% and 8.8% 
respectively. 
 
Anxiety, co-existing anxiety/depression and, particularly, depression alone, were associated 
with higher prevalence of chronic breathlessness. (Table 2; Figure 1a). Similarly, co-existing 
anxiety/depression was associated with a longer duration of breathlessness (Figure 2). 
 
In multinomial regression analyses with psychological morbidity as the dependent outcome, 
older age, longer duration of breathlessness, and worse functional status (AKPS ≤60) 
predicted depression only and co-existing anxiety/depression (Table 3). The relationship 
between poor functional status and psychological morbidity was striking (Figure 1b), 
especially in relation to the presence of co-existing anxiety/depression (OR 16.1; 95% 8.3, 
31.4). The factors associated with anxiety only were sex, where men were less likely than 
women to be anxious, older age and duration of breathlessness. 
 
From multivariate analysis, results relating to experiencing breathlessness are presented in 
Table 4. In comparison to those with no anxiety or depression, those in the depression only 
group and the co-existing anxiety/depression groups showed a significant increase in the 
prevalence of breathlessness. The odds of breathlessness were estimated to be 5.5 times 
higher among the depression only group (AOR=5.5, 95% CI 2.3,12.9) and 5.1 times higher 





The presence of clinically important breathlessness (mMRC ≥2) was strongly associated with 
the presence of clinically relevant levels of psychological morbidity in a cross-sectional 
community cohort of adults with prevalence of chronic breathlessness similar to previous 
studies in the Australian population. [6] Although the relationship between COPD and 
depression is well documented, this current study defines the relationship between 
breathlessness, anxiety and depression, in a representative community population, and not 
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contacted because of their use of health services. The association extends to all adult age 
groups, with findings from a study in the elderly showing the same strong associations. [13] 
The very strong association between poorer functional status and psychological morbidity has 
not previously been described at the population level. Similarly, the association between 
duration of breathlessness and psychological morbidity is a new finding that has not been 
described in population-based studies.  
 
Although the findings of a strong association between breathlessness, depression and co-
existent depression/anxiety may not be surprising, this is the first time that the relationship 
has been documented in this way and a lack of association with anxiety alone demonstrated.  
 
This study reflects similar results to randomly selected households where one member was 
interviewed face-to-face across a representative sample of one Australian state using the same 
question for chronic breathlessness that combined the mMRC and a time frame. [6] The 
overall rate of mMRC ≥2 was the same (2.4% in this study versus 2.6% in the previous 
study). [6]   
 
The association between longer duration of breathlessness and psychological morbidity was 
an important finding. One possible explanation is that longer duration of breathlessness is 
correlated with more advanced disease and worse function, factors that may contribute to 
anxiety and/or depression. However, people who experience breathlessness for long periods 
also undergo structural brain changes affecting limbic and peri-limbic regions, which regulate 
emotions and were shown to be associated with fear of breathlessness in people with chronic 
breathlessness. [26,27] Thus, such changes may contribute to anxiety, depression or both in 
this population. 
 
Causes of chronic breathlessness include advanced respiratory disease and chronic heart 
failure. The relationship between disease severity, symptom severity and functional abilities 
is complex and even in clinical cohorts, not well defined. [28] From a large meta-analysis in 
clinical studies, more severe heart failure was associated with worsening functional status and 
higher likelihood of depression. [28] Likewise, in COPD, the relationship between disease, 
symptom and functional decline has been defined in large prospective and cross sectional 
studies. [29] However, this is the first population-based study to explore the relationship 
between chronic breathlessness and functional status at a population level. 
 
Two large evaluation-phase placebo controlled trials of medications that may address anxiety 
(buspirone, sertraline) or depression (sertraline) in the presence of chronic breathlessness 
have been strongly negative. [18,19] Given the strong association of anxiety and depression 
with chronic breathlessness, this may seem surprising. However, the trial populations were 
not those with breathlessness and psychological comorbidity and thus not powered to identify 
benefit in a sub-group with clinically significant anxiety/depression.   
 
Functional decline is a final common pathway through many chronic complex conditions as 
they become chronic, progressive conditions. The relationship between depression and 
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functional decline has been well defined in the elderly and, as seen in this study there is a 
close relationship between co-existing anxiety/depression and functional decline although not 
necessarily between anxiety alone and functional decline. [30] Rate of change in functional 
status is strongly correlated with and predictive of prognosis in cancer and AIDS. [31,32] The 
relationship at a population level of the strong relationship between functional change and 
depression and anxiety is striking and has not been reported before. Functional decline leads 
to decreasing autonomy, loss of independence, increasing social isolation, [33] 
deconditioning which can further worsen breathlessness all of which may contribute to 
aggravating anxious and depressive symptoms. [34] Whether psychological comorbidity is a 
consequence of breathlessness itself or of the functional / social losses imposed by 




This study is based on a purposive population sample using a web-based panel that reaches 
into the community, independent of prior health service contact for the formation of the 
cohort. This therefore more likely reflects the real prevalence of chronic breathlessness, 
functional status, psychological morbidity and their relationship with each other in the 
general population. Australia has very high rates of home internet usage making such web-
based panels highly relevant. The topic of the survey was not revealed before respondents 
engaged. Response rates with internet surveys are now higher than postal or telephone 




This study could only reach people who were members of a web-based panel and therefore 
technologically adept. As such, despite the respondents reflecting the demographics of the 
Australian population from the most recent national census, there may be unquantifiable 
biases in the tech-savvy, internet using respondents, potentially limiting the generalisability 
to the population as a whole. No causality can be assigned, only associations between the 
factors studied. This is especially a concern given the socio-economic gradient for smoking 
tobacco and its causal effect in COPD in the community, potentially underestimating the 
prevalence. The sample engaged were, however, representative of the community for key 
demographic factors of age, sex, state or territory of residence and metropolitan/non-
metropolitan.  
 
The absence of significance for the association between chronic breathlessness and anxiety 
alone in the multivariable model may represent a type II error that may disappear with a 
larger study cohort of people with mMRC breathlessness level 2-4. Data on potential 
confounders of known associations with chronic breathlessness including smoking history, 
heart and lung function, objective measures of daily activities and socioeconomic status were 
unavailable. The study did not seek the respondents’ perceptions of their causes of 
breathlessness because this has been defined previously in cross-sectional population studies 




Implications for clinical practice 
 
This study highlights the need to screen for anxiety and depression in people with 
deteriorating function and in moderate to severe chronic breathlessness. As the population 
becomes more likely to die from chronic progressive conditions, the life-time likelihood of 
functional decline is increasing and screening for anxiety and depression needs to be built 
into clinical care pathways, which should be adequately resourced. In chronic breathlessness, 
such an approach is supported with data showing pre-study and post-study scores of people 
with COPD who engaged with pulmonary rehabilitation where scores for people with either 
anxiety or depression or both raised at baseline fell by a clinically meaningful level for all 
three groups. [35]  
 
Implications for future research 
 
Given the rates of co-existent anxiety/depression found in people with moderate to severe 
chronic breathlessness, a key question will be whether or not the successful symptomatic 
treatment of the person’s chronic breathlessness could predictably reduce anxiety, depression 
or both. Clinical trials into non-pharmacological and pharmacological symptomatic 
treatments for chronic breathlessness need to consider the PHQ4 as a secondary outcome and, 
potentially, even a primary outcome. Conversely, as previous trials have not addressed the 
impact of treating mental health morbidity (for example, a trial population of people with 
anxiety and/or depression and chronic breathlessness), a further key question is whether or 
not successful treatment of anxiety states or clinical depression in those with chronic 
breathlessness improves the symptom of breathlessness. 
 
Data sharing. Data are available on request from bona fide researchers 
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Table 1. Internet-based quota-based national survey study sample compared with the 
Australian population from the 2016 census  




 n (%) n (%) 
Age Category   
    18 – 34 895 (30.1) 5,512,542 (30.3) 
    35 – 44 560 (18.8) 3,144,297 (17.3) 
    45 – 54 538 (18.1) 3,104,299 (17.1) 
    55 – 64 446 (15.0) 2,753,037 (15.1) 
   ≥ 65 538 (18.1) 3,676,064 (20.2) 
   
Sex    
    Male 1,485(49.9) 8,871,622 (48.8) 
    Male 1,492 (50.1) 9,318,617 (51.2) 
   
State or territory   
    NSW 914 (30.7) 5,827,179 (32.0) 
    VIC 763 (25.6) 4,638,884 (25.5) 
    QLD 604 (20.3) 3,611,968 (19.9) 
    SA 228 (7.7) 1,323,884 (7.3) 
    WA 313 (10.5) 1,907,253 (10.5) 
    TAS 69 (2.3) 400,777 (2.2) 
    NT 30 (1.0) 170,694 (0.9) 





Table 2: Relationships between psychological morbidity and key factors from a community 
internet survey of the general population. n=2,977 
   Psychological Morbidity#  
 
p-value 


































































Duration of breathlessness 
(only in those with self-rated 
mMRC≥2; in months) 
Mean (SD) 





























































#PHQ4 scores >3/6 for anxiety; >3/6 for depression as clinically relevant cut points defined each 
symptom; ##mMRC: modified Medical Research Council breathlessness scale; *both ANOVA and 
Kruskal-Wallis test were performed and results were comparable, **AKPS: Australia-modified 




Table 3. Result of multinomial logistic regression analysis, using age, sex, functionality and 
duration chronic breathlessness to predict anxiety, depression or both. 






Depressed# AND anxious## 
vs. 
Neither 
 OR (95% CI) 
Age* (per year) 0.97 (0.95, 0.98) 0.97 (0.96, 0.98) 0.96 (0.94, 0.97) 
Sex (Male versus female) 1.07 (0.69, 1.68) 0.56 (0.41, 0.77) 0.86 (0.63, 1.18) 







1.006 (1.004, 1.008) 
Functionality (AKPS**: 
≤60 versus 100-70)  
4.84 (1.39, 16.77) 1.42 (0.33, 6.17) 16.07 (8.23, 31.39) 
*as a continuous variable; **AKPS: Australia-modified Karnofsky Performance functional status; mMRC: 
modified Medical Research Council breathlessness scale; #Patient Health Questionnaire-2 question (PHQ-2); 




Table 4. Odds ratio and adjusted odds ratio of chronic breathlessness (n=2977) 





Psychological morbidity   
   No anxiety+ or depression++ Ref Ref 
   Depression++ only 6.0 (2.6,13.8) 5.5 (2.3,12.9) 
   Anxiety+ only 2.2 (0.9,5.2) 2.1 (0.9,5.2) 
   Co-existing anxiety+/depression++ 7.3 (4.1,12.9) 5.1 (2.7,9.7) 
(a)odds ratio adjusted for age, sex and functionality;++Patient Health Questionnaire-2 question (PHQ-2); 
+Generalised Anxiety Disorder-2 question (GAD-2). (Together PHQ-2 and GAD-2 are the PHQ-4).  
#modified Medical Research Council (mMRC) breathlessness scale 2-4; ## mMRC 0,1; * Australia-modified 
Karnofsky Performance Status scale 
 
